Cargando…

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies revealed a recurrent pattern of G614 increase at multiple geographic levels: national, regional, and municipal. The shift occurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korber, Bette, Fischer, Will M., Gnanakaran, Sandrasegaram, Yoon, Hyejin, Theiler, James, Abfalterer, Werner, Hengartner, Nick, Giorgi, Elena E., Bhattacharya, Tanmoy, Foley, Brian, Hastie, Kathryn M., Parker, Matthew D., Partridge, David G., Evans, Cariad M., Freeman, Timothy M., de Silva, Thushan I., McDanal, Charlene, Perez, Lautaro G., Tang, Haili, Moon-Walker, Alex, Whelan, Sean P., LaBranche, Celia C., Saphire, Erica O., Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cell Press 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332439/ https://www.ncbi.nlm.nih.gov/pubmed/32697968 http://dx.doi.org/10.1016/j.cell.2020.06.043

Ejemplares similares

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
por: Weissman, Drew, et al.
Publicado: (2021)

The SARS-CoV-2 Spike variant D614G favors an open conformational state
por: Mansbach, Rachael A., et al.
Publicado: (2021)

HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens
por: Fischer, Will, et al.
Publicado: (2021)

The SARS-CoV-2 Spike Variant D614G Favors an Open Conformational State
por: Mansbach, Rachael A., et al.
Publicado: (2021)

Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2
por: Nguyen, Kien, et al.
Publicado: (2021)

Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2
por: Nguyen, Kien, et al.
Publicado: (2021)

Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail
por: Chakraborty, Srirupa, et al.
Publicado: (2020)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Graph‐based optimization of epitope coverage for vaccine antigen design
por: Theiler, James, et al.
Publicado: (2017)

Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies
por: Gnanakaran, S., et al.
Publicado: (2010)

Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine
por: Theiler, James, et al.
Publicado: (2016)

SARS-CoV-2 variant transition dynamics are associated with vaccination rates, number of co-circulating variants, and convalescent immunity
por: Beesley, Lauren J., et al.
Publicado: (2023)

Integrated sequence and immunology filovirus database at Los Alamos
por: Yusim, Karina, et al.
Publicado: (2016)

A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein
por: Sethi, Anurag, et al.
Publicado: (2013)

Impact of mutations near the SARS-CoV-2 furin-cleavage site on viral infectivity
por: Nguyen, Kien, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST
por: Giorgi, Elena E., et al.
Publicado: (2020)

Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein
por: Tian, Jianhui, et al.
Publicado: (2016)

A single, continuous metric to define tiered serum neutralization potency against HIV
por: Hraber, Peter, et al.
Publicado: (2018)

A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity
por: Asmal, Mohammed, et al.
Publicado: (2011)

Essential Dynamics that Drive Sars-Cov-2 Spike Conformational Changes
por: Chakraborty, Srirupa, et al.
Publicado: (2021)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

SARS-CoV-2 antibodies specific to the mesa and inner side of spike protein receptor binding domain maintain high affinities for both D614G and b.1.351 variants
por: Li, Kan, et al.
Publicado: (2022)

Lassa virus glycoprotein: stopping a moving target
por: Hastie, Kathryn M, et al.
Publicado: (2018)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants
por: Hraber, Peter, et al.
Publicado: (2015)

Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

A coarse-grained model for synergistic action of multiple enzymes on cellulose
por: Asztalos, Andrea, et al.
Publicado: (2012)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Estimating time since infection in early homogeneous HIV-1 samples using a poisson model
por: Giorgi, Elena E, et al.
Publicado: (2010)

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster
por: Brustolin, Marco, et al.
Publicado: (2021)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques
por: Pahar, Bapi, et al.
Publicado: (2016)

Stability of SARS-CoV-2 Spike G614 Variant Surpasses That of the D614 Variant after Cold Storage
por: Huang, Sheng-Yu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0352l3n1g4njcluugiecufeoer